# X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

> **NCT03215693** · PHASE2 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 152 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** X-396 capsule

## Key facts

- **NCT ID:** NCT03215693
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-28
- **Primary completion:** 2020-03-09
- **Final completion:** 2023-12
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2023-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03215693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03215693, "X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03215693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*